TuHURA Biosciences (NASDAQ:HURA - Free Report) - Stock analysts at HC Wainwright issued their FY2025 earnings estimates for TuHURA Biosciences in a research report issued on Friday, May 16th. HC Wainwright analyst R. Burns forecasts that the company will post earnings of ($0.56) per share for the year. HC Wainwright has a "Buy" rating and a $12.00 price objective on the stock. HC Wainwright also issued estimates for TuHURA Biosciences' FY2026 earnings at ($0.52) EPS.
TuHURA Biosciences (NASDAQ:HURA - Get Free Report) last posted its quarterly earnings results on Thursday, May 15th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.02).
TuHURA Biosciences Price Performance
Shares of NASDAQ HURA opened at $3.92 on Monday. The firm's 50-day moving average price is $3.68 and its two-hundred day moving average price is $4.07. TuHURA Biosciences has a 52-week low of $1.80 and a 52-week high of $7.93.
Institutional Trading of TuHURA Biosciences
Several hedge funds have recently made changes to their positions in HURA. Accent Capital Management LLC bought a new stake in TuHURA Biosciences in the fourth quarter valued at $29,000. TT Capital Management LLC acquired a new stake in shares of TuHURA Biosciences in the fourth quarter valued at approximately $41,000. Jefferies Financial Group Inc. bought a new stake in shares of TuHURA Biosciences during the fourth quarter valued at approximately $54,000. Bank of America Corp DE acquired a new position in shares of TuHURA Biosciences during the fourth quarter worth approximately $59,000. Finally, Charles Schwab Investment Management Inc. acquired a new position in shares of TuHURA Biosciences during the fourth quarter worth approximately $61,000. Institutional investors own 0.62% of the company's stock.
TuHURA Biosciences Company Profile
(
Get Free Report)
TuHURA Biosciences, Inc NASDAQ: HURA is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider TuHURA Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TuHURA Biosciences wasn't on the list.
While TuHURA Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
